NEW DELHI: The National Technical Advisory Group on Immunization (NTAGI) has approved the Serum Institute’s Covid-19 Covovax for the 12-17 age group. But, no decision has been taken on ...

The Drugs Controller General of India (DCGI) has granted emergency use authorisation (EUA) for the Novavax and Serum Institute of India (SII) Covid-19 vaccine, Covovax, in the 12-18 age group.

A Covid working group of NTAGI will review this week data of Serum Institute of India's (SII) anti-coronavirus jab Covovax to decide whether it can be included in the national COVID-19 vaccination ...

India's drug regulator in July had granted permission to Serum Institute of India (SII) for conducting a phase 2/3 trial of Covovax on children aged 2 to 17 years with certain conditions on the ...

New Delhi: The subject expert committee on COVID-19 of India's drug regulator will on Friday review the applications of Serum Institute of India seeking emergency use authorisation to use Covovax ...

New Delhi: The Drugs Controller General of India (DCGI) granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults ...